Trial Profile
Open-label Phase II Study of Induction Treatment With Folfoxiri Plus Bevacizumab Followed by Preoperative Chemoradiotherapy Plus Bevacizumab in Patients With Locally Advanced, Resectable Rectal Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms TRUST
- 07 Feb 2019 Primary endpoint (Disease-free survival rate at 2 years) has been met as per results published in the European Journal of Cancer
- 07 Feb 2019 Results published in the European Journal of Cancer
- 12 Mar 2018 Status changed from recruiting to completed.